World Alzheimer's Day: How the UAE is making a difference

On World Alzheimer's Day, the United Arab Emirates is making strides in advancing dementia research and care. According to a recent report from Alzheimer’s Disease International, nearly 160 potential therapies are currently undergoing trials worldwide, signaling a potential breakthrough in the treatment of this debilitating cognitive illness.

However, the existing data on global dementia patients predominantly represents western, mostly white populations, and this lack of representation raises concerns for the Middle Eastern population, which is rapidly aging.

The UAE, through its Emirati Genome Programme, has gathered genetic data from nearly a million UAE citizens, offering a unique opportunity to improve dementia research in the region. In July, The National reported on Abu Dhabi's use of this genetic data to identify high-risk individuals for a trial of preventive therapy. The UAE's commitment to scientific experiments is evident, as the country's diverse population is highly willing to participate in such studies.

This participatory goodwill is crucial for plugging research gaps and increasing the number of participants needed for active dementia trials, which currently require approximately 55,000 participants globally.

The UAE's multicultural environment, home to over 200 nationalities, makes it an ideal location for conducting diverse and representative clinical trials. By promoting awareness, facilitating clearer referral pathways, and simplifying the eligibility criteria, the UAE has the potential to lead the region in designing medical trials tailored to its population.

In doing so, the Gulf region can become a hub for scientific discoveries that directly impact the lives of those affected by complex diseases like dementia. This progress in the UAE represents not only a significant step forward in dementia care but also an opportunity to improve the lives of those personally touched by these conditions.